Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3845092 | 0.76 | SCN4A (0.35) | SCN4APRCPPSMB8HTR2CDPP4 | |
| Hydrochloric Acid SCHEMBL3848044 | 0.72 | SCN4A (0.34) | SCN4APRCPHTR2CNOS2NOS3 | |
| Hydrochloric Acid SCHEMBL5976172 | 0.68 | SCN4A (0.35) | SCN4APRCPHTR2CNOS2NOS3 | |
| Iodide SCHEMBL2779949 | 0.66 | SCN4A (0.37) | SCN4APRCPPSMB8HTR2CNOS2 | |
| Iodide SCHEMBL2779957 | 0.66 | SCN4A (0.37) | SCN4APRCPPSMB8HTR2CNOS2 | |
| Hydrochloric Acid SCHEMBL3849537 | 0.65 | POLB (0.52) | — | |
| Hydrochloric Acid SCHEMBL3848048 | 0.65 | NOS2 (0.36) | SCN4APRCPPSMB8NOS2NOS3 | |
| SCHEMBL14296418 | 0.63 | — | — | |
| SCHEMBL878969 | 0.63 | — | — | |
| SCHEMBL514066 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | ALTEON, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | SCN4A 2849/4885PRCP 1068/4885PSMB8 2363/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | SCN4A 2764/4885PRCP 2302/4885PSMB8 2423/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | SCN4A 3265/4885PRCP 719/4885PSMB8 2159/4885 |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, COL2A1 | SCN4A 3136/4885PRCP 1558/4885PSMB8 3671/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | SCN4A 2169/4885PRCP 1669/4885PSMB8 2871/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | SCN4A 2959/4885PRCP 1387/4885PSMB8 2182/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | SCN4A 2685/4885PRCP 1459/4885PSMB8 3956/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | SCN4A 2306/4885PRCP 1119/4885PSMB8 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.